Compare Abbott Laboratories (ABT) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Linde PLC — how do they compare? Abbott Laboratories trades at $95.42 (market cap $166.94B), while Linde PLC trades at $527.93 (market cap $248.85B). The key difference: Linde PLC is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | LIN | |
|---|---|---|
Market Cap | $166.94B | $248.85B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $546.64 |
52-Week Low | $82.57 | $389.38 |
Enterprise Value | $193.69B | $271.21B |
Dividend Yield | 2.63% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Linde (LIN) trades at $540.52, down 1.12% on the day, with a bullish technical outlook supported by moving averages and key resistance at $546. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 20.44% net income margin. Recent news highlights sustainability leadership and strategic growth, while cash flow remains positive despite projected 2026 outflows.
Outlook remains positive with 85.7% analyst buy ratings and a $570.80 consensus price target, suggesting 5.6% upside. Risks include rising debt-to-asset ratio (31.63% in 2025) and valuation concerns (P/E 35.84). The stock offers a dividend yield of approximately 0.3% with consistent shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
